Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
US |
|
American Overseas Group Ltd
OTC:AOREF
|
BM |
|
H
|
Hermes International SCA
XMUN:HMI
|
FR |
|
A
|
argenx SE
F:1AE
|
NL |
|
Shiseido Co Ltd
F:SHDA
|
JP |
|
P
|
Puloon Technology Inc
KOSDAQ:094940
|
KR |
|
E
|
Ecograf Ltd
OTC:ECGFF
|
AU |
Intrinsic Value
Is MDGL undervalued or overvalued?
See the intrinsic value estimate for Madrigal Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
MDGL looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with MDGL’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Madrigal Pharmaceuticals Does
Madrigal Pharmaceuticals is a biopharmaceutical company focused on treating metabolic and liver disease. Its main product is a prescription medicine for adults with noncirrhotic steatohepatitis, a serious form of fatty liver disease now often called MASH. The company does not run a broad drug portfolio; it is centered on this one disease area and the therapy built for it.
- Headquarters
- United States of America US
- Employees
- 915
- IPO date
- Feb 6, 2007
Madrigal Pharmaceuticals has no economic moat
Doctors can choose competing treatments, so Madrigal cannot rely on a captive group of patients or a market that only it can serve. Rezdiffra’s patents protect the drug itself, but do not stop other medicines from treating MASH, and the drug does not become more valuable as more people use it.
Read the full moat analysis
Revenue & Expenses Breakdown
Madrigal Pharmaceuticals Inc
Earnings Waterfall
Madrigal Pharmaceuticals Inc
The intrinsic value for Madrigal Pharmaceuticals Inc (MDGL) under the Base Case is hidden USD.
Compared with the current market price of 439.53 USD, the stock appears hidden.